Skip to main content

Table 4 Gene expression and disease control with XelOX therapy

From: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine

 

CR+PR+SD

PD

total

TS ≤ median

25

5

30

TS > median

17

13

30

ERCC1 ≤ 75th%

35

10

45

ERCC1 > 75th%

8

7

15

  1. Six subjects were not assessable for response; therefore, only 60 subjects each with informative TS and ERCC1 samples from metastatic tumor tissue are included in the analysis between gene expression and disease control. The Fisher exact test p-value was 0.047 for TS and 0.099 for ERCC1.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us